Dr Quentin Anstee
Clinical Senior Lecturer & Consultant Hepatologist

  • Email: quentin.anstee@ncl.ac.uk
  • Telephone: +44 (0) 191 208 7012
  • Address: Institute of Cellular Medicine
    4th Floor, William Leech Building
    The Medical School
    Framlington Place
    Newcastle University
    Newcastle-Upon-Tyne, NE2 4HH

Introduction

Dr Quentin M. Anstee is a Clinical Senior Lecturer in the Institute of Cellular Medicine. A practising clinician, he is also an Honorary Consultant Hepatologist in the Liver Unit at the Freeman Hospital, Newcastle.

Dr Anstee's primary research interest is the study of genetic modifiers of progressive liver disease. His translational research has extended from the bench to the bedside with particular focus on the pathogenesis and treatment of Non-Alcoholic Fatty Liver Disease (NAFLD/NASH), modifiers of Hepatic Fibrosis progression and identification of genetic factors that promote Alcohol Addiction. He is actively involved in ongoing clinical trials of new therapies for fatty liver disease and hepatic fibrosis.

Clinical Expertise

Dr Anstee trained in medicine at University College London where he was awarded First Prize in Medicine in the final MB BS examination (The Philip Seth Belasco & Douglas Cree Prize, 1997).

His post-graduate specialist clinical training in Hepatology/Gastroenterology & General Medicine was undertaken at hospitals in North-West London. Prior to joining ICM, he worked as Clinical Lecturer in Medicine & Hepatology at Imperial College London and St Mary's Hospital from 2007-2010.

Dr Anstee's clinical practice is based in the Regional Liver Unit at the Freeman Hospital. He has expertise in the management of patients with a range of acute and chronic liver conditions including:

  • Non-Alcoholic Fatty Liver Disease & Steatohepatitis (NAFLD/NASH)
  • Chronic Viral Hepatitis (hepatitis B & hepatitis C)
  • Alcoholic Liver Disease
  • Autoimmune hepatitis, PSC & PBC
  • Cirrhosis 

He has a particular sub-specialist interest in the management of non-alcoholic fatty liver disease and, together with Professor Chris Day, runs the regional fatty liver service. He also provides diagnostic and therapeautic endoscopy services at the Freeman Hospital and the Royal Victoria Infirmary, Newcastle. 

Qualifications

  • BSc(Hons) - 1st Class 'Cell Pathology & Basic Medical Sciences', UCL (1994)
  • MB BS with Distinction in Medicine, UCL (1997)
  • MRCP(UK), Royal College of Physicians (London, 2000)
  • PhD, Imperial College London (2007)

Esteem Indicators

Membership of Editorial Boards:

  • Journal of Hepatology

Peer Review Activity:

  • International journals including 'Hepatology', 'Journal of Hepatology', 'Gut', 'Liver International', 'Journal of Viral Hepatitis', 'Mammalian Genome' & 'International Journal of Experimental Pathology'
  • Grant awarding bodies including the MRC, Wellcome Trust and NIHR.

Invited Lectures at Recent National & International Meetings:

  • 'NASH - Diagnosis & Current Management' Co-chair of Early Morning Workshop, 49th International Liver Congress, European Association for the Study of the Liver, 2014, London, UK.
  • 'Genetics of NAFLD & ALD' Falk Forum on Autoimmune & Congenital Liver Disorders, 2014, London, UK. 
  • 'Genetics of NAFLD' & 'New Therapies for NAFLD' NAFLD: Basics to Clinical Practice - An INASL Initiative, 2014, Chandigarh, India. 
  • 'NAFLD: Clinical Research Update' British Society of Gastroenterology, 2013, Glasgow, UK.
  • 'SNPs, GWAS & NGS - Making Sense of the Alphabet Soup of Genomics' APASL, 2013, Singapore.
  • 'Targeting Patients at Risk of Progressive Non-Alcoholic Fatty Liver Disease - Whom and How?' 47th International Liver Congress, European Association for the Study of the Liver, 2012, Barcelona, Spain.
  • 'Experimental Models of NAFLD'  47th International Liver Congress, European Association for the Study of the Liver, 2012, Barcelona, Spain.
  • 'Targeted Therapy for Non-Alcoholic Fatty Liver Disease & The Metabolic Syndrome' Frontiers in Hepatology 2011, The Institute of Hepatology, London, UK.
  • 'Anticoagulants as Antifibrotics – Current Evidence in Man & Future Trials' 4th International Conference on Coagulopathy in Liver Disease, 2011, London, UK.
  • 'NASH - Pathogenesis & Management' Co-chair of Early Morning Workshop, 46th International Liver Congress, European Association for the Study of the Liver, 2011, Berlin, Germany.
  • 'The Role of Hypercoagulability in the Pathogenesis of Liver Fibrosis' 46th International Liver Congress, European Association for the Study of the Liver, 2011, Berlin, Germany.
  • 'Fatty Liver Disease & The Metabolic Syndrome' Frontiers in Hepatology 2010, The Institute of Hepatology, London, UK.
  • 'Pathophysiological Basis of Non-Alcoholic Steatohepatitis' British Association for the Study of the Liver 2010, Edinburgh, UK.
  • 'Mechanisms of Fibrogenesis – Metabolic Factors' European Young Hepatologist Workshop 2010, France.

Memberships

  • Collegiate Member of the Royal College of Physicians of London
  • British Association for the Study of the Liver (BASL)
  • European Association for the Study of the Liver (EASL)
  • American Association for the Study of the Liver (AASLD)

Research Interests

Dr Anstee's primary research interest is the study of genetic modifiers of progressive liver disease. His translational research has extended from the bench to the bedside with particular focus on the pathogenesis and treatment of Non-Alcoholic Fatty Liver Disease (NAFLD/NASH), modifiers of Hepatic Fibrosis progression and identification of genetic factors that promote Alcohol Addiction. He has ongoing fruitful collaborations with both industrial and scientific partners at other UK and international liver units and is a member of the European Union FP7 funded Fatty Liver: Inhibition of Progression (FLIP) Consortium.

Dr Anstee's scientific research has employed gene-driven and phenotype‐driven ethyl-nitrosourea (ENU) mutagenesis screens and more traditional targeted genetic modification techniques to generate and study models of complex genetic disease traits including alcohol addiction, non-alcoholic steatohepatitis, drug induced liver injury (paracetamol toxicity and antibiotic related idiosyncratic drug reactions), primary biliary cirrhosis and liver fibrosis. His research is facilitated by his role as an Honorary Group Leader of the Liver Group at the MRC Mammalian Genetics Unit, MRC Harwell.

His research has led to an MRC Experimental Medicine funded clinical trial examining the efficacy of anticoagulation to slow graft fibrosis in hepatitis C infected liver transplant patients (WAFT-C) and studies of novel therapies in NAFLD/NASH including caspase inhibition and gut flora modulation (RiFL). He is a principal investigator in ongoing clinical trials of new therapies for fatty liver disease and hepatic fibrosis.


Funding

Dr Anstee is the recipient of a HEFCE Clinical Senior Lecturer Award. He has previously received an MRC Clinical Research Fellowship to study genetic modifiers of Non-Alcoholic Steatohepatitis (NASH) & Liver Fibrosis.

He has received research grant funding from sources including the MRC, Wellcome Trust, Academy of Medical Sciences and the NIHR Biomedical Research Centres at Newcastle University & Imperial College.

Undergraduate Teaching

  • Medicine & Surgery MB BS Course (CSIM3): Lecturer
  • Medicine & Surgery MB BS Course (NME2): Seminar Tutor
  • Biomedical Sciences BSc Course (BMS3020 - Chronic Disease): Lecturer
  • Biomedical Sciences BSc Course (BGM3061 - Integrated Genetics): Lecturer
  • MB BS Undergraduate Tutor

Lecture topics include: 'Non-Alcoholic Fatty Liver Disease (NAFLD)', 'Alcoholic Liver Disease', 'Viral Hepatitis (hepatitis C)', 'Cirrhosis & its Complications', 'Genetics of NAFLD'.

Postgraduate Teaching 

  • Medical Sciences MRes: Senior Tutor for Intercalating Students
  • MRes (Diabetes): Lecturer
  • MClinRes (MCR8006: Designing a Research Proposal): Lecturer
  • MClinRes (MCR8004: Developing Your Career in Clinical Research): Lecturer